Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow QGEN by emailGet an email when QGEN pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about QGEN, unsubscribe in one click. Privacy
📣 What QGEN Says Is Next
in 2026 · “New QIAcuity gene expression assays and a high-multiplex kit enabling analysis of up to 12 RNA targets in a single reaction are being launched in 2026.”
Company press release, Aug 7, 2026 · SEC filing
late 2027 · “Targeted for launch in late 2027, the workflow is designed to improve efficiency and standardization in high-throughput latent TB screening.”
Company press release, Aug 7, 2026 · SEC filing
H2 2026 · “QIAGEN continued to see healthy interest in the new QIAsymphony Connect and QIAsprint Connect systems, while QIAmini remains on track for launch in H2 2026.”
Company press release, Aug 7, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full QGEN picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for QGEN and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.